Further results have confirmed that EA increases Nrf2 expression, followed by the upregulation of the key molecules SLC7A11, FTH1, and GPX4 to improve mitochondrial dysfunction, thus relieving PD symptoms by inhibiting the ferroptosis of DAergic neurons. The gene discussed is NFE2L2; the disease is Parkinson disease.